| Withdrawn | Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, Sickle Cell Disease | Phase 3 | 2027-07-31 |
| Not Yet Recruiting | A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis Myasthenia Gravis, Generalized | Phase 2 | 2026-04-16 |
| Recruiting | Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants Cystic Fibrosis | Phase 1 | 2026-02-25 |
| Recruiting | Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants Pain | Phase 1 | 2026-02-13 |
| Completed | Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participan Cystic Fibrosis | Phase 1 | 2026-01-12 |
| Recruiting | Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants Cystic Fibrosis | Phase 1 | 2025-12-09 |
| Recruiting | Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy Diabetic Peripheral Neuropathic Pain | Phase 3 | 2025-11-21 |
| Recruiting | Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW) Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Phase 2 | 2025-11-19 |
| Recruiting | A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Primary Membranous Nephropathy | Phase 2 / Phase 3 | 2025-09-30 |
| Completed | Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Phase 1 | 2025-07-11 |
| Completed | A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Phase 1 | 2025-06-12 |
| Completed | A Study to Evaluate the Relative Bioavailability of Povetacicept Formulations and Bioequivalence of Povetacice Healthy Volunteers | Phase 1 | 2025-06-06 |
| Enrolling By Invitation | A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I Myotonic Dystrophy Type 1 (DM1) | Phase 2 | 2025-04-28 |
| Completed | A Phase 1 Study to Evaluate the Relative Bioavailability of a VX-828 Tablet Formulation Cystic Fibrosis | Phase 1 | 2025-04-01 |
| Recruiting | An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Trans Type 1 Diabetes, Kidney Transplant | Phase 3 | 2025-03-31 |
| Completed | A Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Selected Acute Pain | Phase 4 | 2025-03-27 |
| Completed | A Study to Evaluate How the Body Processes 14C-VX-993 After a Single Oral Dose Pain | Phase 1 | 2025-03-21 |
| Completed | A Single-Arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Aesthetic Acute Pain | Phase 4 | 2025-03-21 |
| Completed | A Study of Suzetrigine (SUZ) Spray-dried Dispersion (SSD) in Healthy Adult Panelists Pain | Phase 1 | 2025-03-10 |
| Completed | Evaluation of the Effect of Suzetrigine (SUZ) on the Pharmacokinetics of Oral Contraceptives in Healthy Female Pain | Phase 1 | 2025-02-25 |
| Recruiting | Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities Proteinuric Kidney Disease | Phase 2 | 2025-02-04 |
| Active Not Recruiting | Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease Autosomal Dominant Polycystic Kidney Disease (ADPKD) | — | 2024-12-19 |
| Active Not Recruiting | Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabeti Diabetic Peripheral Neuropathic Pain | Phase 3 | 2024-12-18 |
| Active Not Recruiting | Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age an Cystic Fibrosis | Phase 3 | 2024-11-21 |
| Completed | A Study Evaluating Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy Acute Pain | Phase 2 | 2024-10-29 |
| Recruiting | Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy Diabetic Peripheral Neuropathic Pain | Phase 2 | 2024-10-18 |
| Recruiting | Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy Diabetic Peripheral Neuropathic Pain | Phase 3 | 2024-10-01 |
| Completed | A Phase 1 Dose Escalation Study of VX-973 in Healthy Participants Pain | Phase 1 | 2024-09-30 |
| Completed | Evaluation of the Pharmacokinetics and Safety of Inaxaplin in Participants With Mild or Moderate Hepatic Impai Focal Segmental Glomerulosclerosis (FSGS) | Phase 1 | 2024-08-02 |
| Completed | Evaluation of the Pharmacokinetic Drug-drug Interactions Between VX-993 and Metformin in Healthy Adults Pain | Phase 1 | 2024-07-31 |
| Completed | A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-993 Pain | Phase 1 | 2024-07-26 |
| Completed | Natural History Study of Exocrine Pancreatic Function in Infants With Cystic Fibrosis (CF) Cystic Fibrosis | — | 2024-07-09 |
| Completed | A Microneurography Study of NaV1.8 Inhibition in Healthy Adults Pain | Phase 1 | 2024-05-21 |
| Completed | A Phase 1 Dose Escalation Study of Intravenous VX-993 in Healthy Adults Pain | Phase 1 | 2024-05-09 |
| Completed | A Phase 1, Open-label Study Evaluating the Pharmacokinetics and Drug-drug Interaction of VX-993 in Healthy Adu Pain | Phase 1 | 2024-05-02 |
| Completed | A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Phase 1 | 2024-04-17 |
| Completed | A Study to Evaluate the Relative Bioavailability and Food Effect of a VX-118 Tablet Formulation Cystic Fibrosis | Phase 1 | 2024-04-02 |
| Completed | A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation and Strength of S Pain | Phase 1 | 2024-03-28 |
| Completed | A Study of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) in Healthy Adult Panelists Cystic Fibrosis | Phase 1 | 2024-03-26 |
| Completed | A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulati Cystic Fibrosis | Phase 1 | 2024-03-13 |
| Recruiting | A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) Myotonic Dystrophy Type 1 (DM1) | Phase 1 / Phase 2 | 2024-02-20 |
| Completed | A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics, of VX-993 Pain | Phase 1 | 2024-01-04 |
| Completed | Evaluation of Efficacy and Safety of VX-548 for Painful Lumbosacral Radiculopathy (PLSR) Painful Lumbosacral Radiculopathy | Phase 2 | 2023-12-13 |
| Recruiting | Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis Cystic Fibrosis | Phase 1 | 2023-12-12 |
| Enrolling By Invitation | Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Partici Cystic Fibrosis | Phase 3 | 2023-08-11 |
| Completed | A Study Evaluating the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-147 Focal Segmental Glomerulosclerosis (FSGS) | Phase 1 | 2023-07-19 |
| Completed | Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less T Cystic Fibrosis | Phase 3 | 2023-06-27 |
| Completed | A Study to Evaluate Pharmacokinetics (PK) and Safety of Inaxaplin in Participants With Renal Impairment Renal Impairment | Phase 1 | 2023-06-12 |
| Active Not Recruiting | A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes Type 1 Diabetes | Phase 1 / Phase 2 | 2023-05-16 |
| Completed | A Phase 1 Dose Escalation Study of VX-973 in Healthy Adults Pain | Phase 1 | 2023-05-10 |
| Completed | A Study to Evaluate the Effect of Food on the Pharmacokinetics of VX-548 Pain | Phase 1 | 2023-05-03 |
| Completed | An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy Participant Cystic Fibrosis | Phase 1 | 2023-04-26 |
| Completed | A Study to Evaluate the Effect of VX-548 on the QT/QTc Interval in Healthy Participants Pain | Phase 1 | 2023-04-12 |
| Recruiting | A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF) Cystic Fibrosis | Phase 1 / Phase 2 | 2023-02-27 |
| Completed | Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Renal Impairment Pain | Phase 1 | 2023-02-27 |
| Terminated | A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype Alpha-1 Antitrypsin Deficiency | Phase 2 | 2023-02-23 |
| Completed | A Phase 1, First-in-human Study of VX-668 Alpha-1 Antitrypsin Deficiency | Phase 1 | 2023-02-08 |
| Completed | A Single-arm Study to Evaluate Safety and Effectiveness of VX-548 for Acute Pain Pain | Phase 3 | 2023-01-09 |
| Completed | Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN) Diabetic Peripheral Neuropathy | Phase 2 | 2022-12-20 |
| Completed | Evaluation of the Effects of Omeprazole and Rifampin on the Pharmacokinetics of VX-548 in Healthy Participants Pain | Phase 1 | 2022-12-15 |
| Completed | A Phase 1 Dose Escalation Study of VX-993 in Healthy Participants Pain | Phase 1 | 2022-12-14 |
| Active Not Recruiting | Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Wit Cystic Fibrosis | Phase 3 | 2022-11-23 |
| Active Not Recruiting | A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy Cystic Fibrosis | Phase 3 | 2022-11-08 |
| Completed | Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Mild or Moderate Hepatic Impairme Pain | Phase 1 | 2022-10-14 |
| Completed | A Phase 1, First-in-human Study of VX-634 Alpha 1-Antitrypsin Deficiency | Phase 1 | 2022-10-13 |
| Completed | Evaluation of Efficacy and Safety of Suzetrigine for Acute Pain After an Abdominoplasty Acute Pain | Phase 3 | 2022-10-10 |
| Completed | Evaluation of Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy Acute Pain | Phase 3 | 2022-10-03 |
| Completed | A Study to Evaluate the Pharmacokinetic Drug-drug Interactions Between VX-548, Midazolam, and Digoxin Pain | Phase 1 | 2022-09-22 |
| Completed | A Phase 1 Dose Escalation Study of VX-708 in Healthy Participants Pain | Phase 1 | 2022-09-17 |
| Completed | A Study to Evaluate the Relative Bioavailability of a Fixed-dose Combination Tablet of VX-121/Tezacaftor/Deuti Cystic Fibrosis | Phase 1 | 2022-09-15 |
| Recruiting | Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thal Beta-Thalassemia, Thalassemia, Hematologic Diseases | Phase 3 | 2022-08-02 |
| Completed | Pharmacokinetics and Safety Assessment of VX-121/Tezacaftor/Deutivacaftor in Participants With Moderate Hepati Cystic Fibrosis | Phase 1 | 2022-07-22 |
| Completed | A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-548 Pain | Phase 1 | 2022-07-13 |
| Recruiting | Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age Cystic Fibrosis | Phase 3 | 2022-06-21 |
| Completed | A Microneurography (MNG) Study of VX-150 in Healthy Participants Pain | Phase 1 | 2022-06-16 |
| Completed | Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subject Cystic Fibrosis | Phase 3 | 2022-05-09 |
| Active Not Recruiting | Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn | Phase 3 | 2022-05-03 |
| Active Not Recruiting | Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD) Sickle Cell Disease, Hydroxyurea Failure, Hydroxyurea Intolerance | Phase 3 | 2022-05-02 |
| Completed | A Phase 1 Dose Escalation Study of Oral VX-708 in Healthy Participants Acute Pain | Phase 1 | 2022-04-08 |
| Completed | A Phase 1 Dose Escalation Study to Evaluate Safety and Pharmacokinetics (PK) of VX-840 in Healthy Participants APOL1-mediated Kidney Disease | Phase 1 | 2022-04-07 |
| Recruiting | Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Proteinuric Kidney Disease | Phase 2 / Phase 3 | 2022-03-30 |
| Completed | Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Ol Cystic Fibrosis | Phase 3 | 2022-01-17 |
| Completed | A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participants With Cystic Fibrosis (CF) Cystic Fibrosis | Phase 3 | 2022-01-14 |
| Completed | A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del Cystic Fibrosis | Phase 3 | 2021-10-27 |
| Completed | A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Participants With Cystic Fibrosis (CF) Cystic Fibrosis | Phase 3 | 2021-10-12 |
| Completed | A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508d Cystic Fibrosis | Phase 3 | 2021-09-14 |
| Completed | A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty Acute Pain | Phase 2 | 2021-08-30 |
| Completed | A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy Acute Pain | Phase 2 | 2021-07-19 |
| Completed | A Decentralized Study to Evaluate Physical Activity and Cough Frequency Using Wearable Technology in Cystic Fi Cystic Fibrosis | — | 2021-06-30 |
| Recruiting | A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, Severe Hypoglycemia | Phase 3 | 2021-03-29 |
| Enrolling By Invitation | A Long-term Follow-up Study in Participants Who Received CTX001 Beta-Thalassemia, Thalassemia, Sickle Cell Disease | Phase 3 | 2021-01-20 |
| Completed | A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF) Cystic Fibrosis | Phase 3 | 2021-01-15 |
| Completed | A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (C Cystic Fibrosis | Phase 3 | 2021-01-11 |
| Completed | Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years Cystic Fibrosis | Phase 3 | 2020-11-19 |
| Completed | Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype Alpha1-Antitrypsin Deficiency | Phase 2 | 2020-07-24 |
| Completed | A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of A Cystic Fibrosis | Phase 3 | 2020-06-19 |
| Completed | Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis Glomerulosclerosis, Focal Segmental | Phase 2 | 2020-06-08 |
| Completed | A Study Evaluating the Long-Term Safety of Elexacaftor Combination Therapy Cystic Fibrosis | Phase 3 | 2020-05-04 |
| Completed | Long-term Safety of Lumacaftor/Ivacaftor in Participants With Cystic Fibrosis Who Are Homozygous for F508del a Cystic Fibrosis | Phase 3 | 2020-02-24 |
| Completed | Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Cystic Fibrosis | Phase 3 | 2020-02-17 |
| Terminated | Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype Alpha 1-Antitrypsin Deficiency | Phase 2 | 2020-01-13 |
| Completed | Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy Cystic Fibrosis | Phase 3 | 2019-12-05 |
| Completed | A Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozyg Cystic Fibrosis | Phase 3 | 2019-10-03 |
| Completed | A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Cystic Fibrosis | Phase 3 | 2019-08-28 |
| Completed | A Study Evaluating the Long-term Safety of VX-445 Combination Therapy Cystic Fibrosis | Phase 3 | 2019-08-09 |
| Completed | A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Cystic Fibrosis | Phase 2 | 2019-04-30 |
| Completed | A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibr Cystic Fibrosis | Phase 2 | 2019-04-17 |
| Completed | A Dose-ranging Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionect Acute Pain | Phase 2 | 2018-12-12 |
| Completed | A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease Sickle Cell Disease, Hematological Diseases, Hemoglobinopathies | Phase 2 / Phase 3 | 2018-11-27 |
| Completed | A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy Cystic Fibrosis | Phase 3 | 2018-10-09 |
| Completed | Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age Cystic Fibrosis | Phase 3 | 2018-10-02 |
| Completed | A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn | Phase 2 / Phase 3 | 2018-09-14 |
| Completed | Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cy Cystic Fibrosis | Phase 3 | 2018-09-07 |
| Completed | A Study to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Year Cystic Fibrosis | Phase 2 | 2018-08-10 |
| Completed | A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F) Cystic Fibrosis | Phase 3 | 2018-08-03 |
| Terminated | Evaluation of VX-659/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age Cystic Fibrosis | Phase 3 | 2018-08-03 |
| Terminated | A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy Cystic Fibrosis | Phase 3 | 2018-07-13 |
| Completed | A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mu Cystic Fibrosis | Phase 3 | 2018-06-15 |
| Completed | A Study to Evaluate Efficacy and Safety of TEZ/IVA in Subjects Aged 6 Through 11 Years With Cystic Fibrosis Cystic Fibrosis | Phase 3 | 2018-05-17 |
| Completed | A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F) Cystic Fibrosis | Phase 3 | 2018-05-01 |
| Completed | A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F50 Cystic Fibrosis | Phase 3 | 2018-04-25 |
| Completed | Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis Cystic Fibrosis | Phase 1 / Phase 2 | 2018-03-20 |
| Completed | A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mu Cystic Fibrosis | Phase 3 | 2018-03-07 |
| Completed | A Study to Evaluate the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber Neu Small Fiber Neuropathy | Phase 2 | 2017-09-20 |
| Completed | A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Participants With Cystic Fibrosis Who Are L Cystic Fibrosis | Phase 3 | 2017-08-16 |
| Completed | A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Cystic Fibrosis | Phase 2 | 2017-08-08 |
| Completed | A Study to Evaluate Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Have a 3849 + 10KB C→T or D1152 Cystic Fibrosis | Phase 3 | 2017-07-18 |
| Completed | A Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy Acute Pain | Phase 2 | 2017-06-29 |
| Completed | A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA in Orkambi® (Lumacaftor/Ivacaftor) -Experien Cystic Fibrosis | Phase 3 | 2017-05-24 |
| Completed | A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homoz Cystic Fibrosis | Phase 3 | 2017-05-12 |
| Completed | Lumacaftor/Ivacaftor Combination Therapy in Subjects With CF Who Have an A455E CFTR Mutation Cystic Fibrosis | Phase 2 | 2017-01-31 |
| Completed | A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis Cystic Fibrosis | Phase 1 / Phase 2 | 2017-01-23 |
| Terminated | Study to Evaluate the Safety and Efficacy of CTP-656 in Patients With Cystic Fibrosis With CFTR Gating Mutatio Cystic Fibrosis | Phase 2 | 2016-12-01 |
| Completed | A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibros Cystic Fibrosis | Phase 1 | 2016-11-01 |
| Completed | A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis Cystic Fibrosis | Phase 2 | 2016-11-01 |
| Completed | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects W Cystic Fibrosis | Phase 3 | 2016-11-01 |
| Completed | A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis Cystic Fibrosis | Phase 2 | 2016-10-01 |
| Completed | A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosi Cystic Fibrosis | Phase 4 | 2016-09-01 |
| Completed | A Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects Cystic Fibrosis | Phase 2 | 2016-09-01 |
| Completed | A Study Evaluating Safety and Pharmacokinetics of VX-440 in Combination With Tezacaftor/Ivacaftor in Healthy A Cystic Fibrosis | Phase 1 | 2016-07-20 |
| Terminated | Study to Assess the Efficacy and Safety of VX-210 in Subjects With Acute Traumatic Cervical Spinal Cord Injury Cervical Spinal Cord Injury | Phase 2 / Phase 3 | 2016-07-01 |
| Completed | A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fi Cystic Fibrosis | Phase 3 | 2016-06-02 |
| Terminated | A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumacaftor/Ivacaftor Adherence in C Cystic Fibrosis | Phase 4 | 2016-06-01 |
| Terminated | A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years W Cystic Fibrosis | Phase 3 | 2016-05-01 |
| Completed | Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibros Cystic Fibrosis | Phase 3 | 2016-05-01 |
| Completed | A Phase 2 Study to Evaluate Effects of VX-661/Ivacaftor on Lung and Extrapulmonary Systems in Subjects With Cy Cystic Fibrosis | Phase 2 | 2016-02-01 |
| Completed | A Study to Confirm the Long-term Safety and Effectiveness of Kalydeco in Patients With Cystic Fibrosis Who Hav Cystic Fibrosis | — | 2015-12-01 |
| Completed | A Study of the Efficacy and Safety of VX-150 in Subjects With Osteoarthritis of the Knee Osteoarthritis | Phase 2 | 2015-12-01 |
| Completed | A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years Cystic Fibrosis | Phase 3 | 2015-08-01 |
| Completed | Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Cystic Fibrosis | Phase 3 | 2015-08-01 |
| Completed | A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor i Cystic Fibrosis | Phase 3 | 2015-08-01 |
| Completed | A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, H Cystic Fibrosis | Phase 3 | 2015-07-01 |
| Completed | A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Ol Cystic Fibrosis | Phase 3 | 2015-06-01 |
| Completed | Observational Study of Outcomes in Cystic Fibrosis Patients With Selected Gating Mutations on a CFTR Allele (T Cystic Fibrosis | — | 2015-04-01 |
| Completed | Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lu Cystic Fibrosis, Advanced Lung Disease | Phase 3 | 2015-03-01 |
| Completed | A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in S Cystic Fibrosis | Phase 3 | 2015-03-01 |
| Completed | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX Cystic Fibrosis | Phase 3 | 2015-01-01 |
| Completed | Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis Cystic Fibrosis | Phase 2 | 2014-03-01 |
| Completed | An Open-Label, Phase 1 Study in Healthy Adult Subjects to Examine the Effects of Multiple-Dose Ciprofloxacin o Cystic Fibrosis | Phase 1 | 2014-01-01 |
| Completed | Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Transmembrane Conductance Regulat Cystic Fibrosis | Phase 3 | 2013-12-01 |
| Completed | A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cysti Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation | Phase 3 | 2013-10-01 |
| Completed | A Phase 1 Study to Investigate the Food Effect of Lumacaftor in Combination With Ivacaftor Cystic Fibrosis | Phase 1 | 2013-07-01 |
| Completed | Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Cystic Fibrosis | Phase 3 | 2013-07-01 |
| Completed | A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclata Chronic Hepatitis C, CHC, HCV | Phase 2 | 2013-06-01 |
| Completed | Phase 1 PK Interaction Study Between VX-509 and Prednisone or Methylprednisolone in Healthy Male Subjects Drug Interactions | Phase 1 | 2013-06-01 |
| Completed | Study of Lumacaftor in Combination With Ivacaftor in Subjects With Moderate Hepatic Impairment and Healthy Sub Hepatic Impairment, Healthy | Phase 1 | 2013-06-01 |
| Completed | Phase 1, QT/QTC Interval Study in Healthy Subjects Cystic Fibrosis | Phase 1 | 2013-06-01 |
| Completed | A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Ar Cystic Fibrosis, Homozygous for the F508del CFTR Mutation | Phase 3 | 2013-05-01 |
| Completed | An Ocular Safety Study of Ivacaftor-Treated Pediatric Patients 11 Years of Age or Younger With Cystic Fibrosis Cystic Fibrosis | — | 2013-05-01 |
| Completed | A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in Subjects With Rheumatoid Arthritis | Phase 2 / Phase 3 | 2013-04-01 |
| Completed | A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Ar Cystic Fibrosis, Homozygous for the F508del CFTR Mutation | Phase 3 | 2013-04-01 |
| Completed | Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation Cystic Fibrosis | Phase 3 | 2013-02-01 |
| Completed | A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combi Cystic Fibrosis | Phase 1 | 2013-01-01 |
| Completed | A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthrit Rheumatoid Arthritis | Phase 2 | 2013-01-01 |
| Terminated | An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Ped Hepatitis C | Phase 1 / Phase 2 | 2013-01-01 |
| Completed | Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CFTR Gating Mutation Cystic Fibrosis | Phase 3 | 2013-01-01 |
| Completed | A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C | Phase 2 | 2012-11-01 |
| Completed | Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFT Cystic Fibrosis | Phase 2 | 2012-09-01 |
| Completed | Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Reg Cystic Fibrosis | Phase 3 | 2012-07-01 |
| Completed | Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regul Cystic Fibrosis | Phase 3 | 2012-07-01 |
| Completed | VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C Chronic Hepatitis C Virus | Phase 2 | 2012-07-01 |
| Completed | 24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate Rheumatoid Arthritis | Phase 2 | 2012-04-01 |
| Completed | A Study to Investigate VX-787 Given to Adult Volunteers Inoculated With Live Influenza Virus Influenza Virus | Phase 2 | 2012-03-01 |
| Completed | Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del- Cystic Fibrosis | Phase 2 | 2012-02-01 |
| Completed | A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ri Chronic Hepatitis C Virus | Phase 2 | 2012-02-01 |
| Terminated | An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infecti Hepatitis C | Phase 2 | 2012-02-01 |
| Terminated | Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African Ame Hepatitis C | Phase 4 | 2012-01-01 |
| Completed | A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects Chronic Hepatitis C | Phase 1 | 2012-01-01 |
| Terminated | A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepati Hepatitis C | Phase 3 | 2011-12-01 |
| Terminated | A Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial Epilepsy Epilepsy | Phase 2 | 2011-12-01 |
| Terminated | Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Hepatitis C, Chronic | Phase 3 | 2011-11-01 |
| Completed | Study of the Effect of Ivacaftor on Lung Clearance Index in Subjects With Cystic Fibrosis and the G551D Mutati Cystic Fibrosis | Phase 2 | 2011-01-01 |
| Completed | Drug-Drug Interaction Study Between Telaprevir and Buprenorphine Hepatitis C, Opioid-Related Disorders | Phase 1 | 2011-01-01 |
| Completed | Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygo Cystic Fibrosis | Phase 2 | 2010-10-01 |
| Completed | Drug-Drug Interaction Study of VX-770 and VX-809 in Healthy Subjects Cystic Fibrosis | Phase 1 | 2010-10-01 |
| Completed | Study of the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fi Cystic Fibrosis | Phase 2 | 2010-10-01 |
| Completed | Study of VX-770 in Subjects With Moderate Hepatic Impairment and in Matched Healthy Subjects In Development for Cystic Fibrosis | Phase 1 | 2010-09-01 |
| Terminated | A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genot Chronic Hepatitis C Virus Infection | Phase 2 | 2010-08-01 |
| Completed | Rollover Study of VX-770 in Cystic Fibrosis Subjects Cystic Fibrosis | Phase 3 | 2010-07-01 |
| Completed | Study of VX-770 on Desipramine In Development for Cystic Fibrosis | Phase 1 | 2010-06-01 |
| Completed | Study of VX-985 in Subjects With Chronic Hepatitis C Chronic Hepatitis C | Phase 1 | 2010-06-01 |
| Completed | Study of VX-770 on Midazolam and Rosiglitazone and the Effect of Fluconazole on VX-770 Cystic Fibrosis | Phase 1 | 2010-02-01 |
| Completed | A 12-week Study of 4 Doses of VX-509 in Subjects With Active Rheumatoid Arthritis Rheumatoid Arthritis | Phase 2 | 2010-02-01 |
| Completed | Study of VX-765 in Subjects With Treatment-resistant Partial Epilepsy Partial Epilepsy | Phase 2 | 2010-01-01 |
| Completed | A Study to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus in Healthy Hepatitis C | Phase 1 | 2010-01-01 |
| Completed | Study of VX-770 and Rifampin in Healthy Male Subjects Cystic Fibrosis | Phase 1 | 2009-11-01 |
| Completed | Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infec Hepatitis C, HIV Infections | Phase 2 | 2009-10-01 |
| Completed | Drug-Drug Interaction Study of VX-809 and VX-770 in Healthy Subjects Cystic Fibrosis | Phase 1 | 2009-09-01 |
| Terminated | Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutatio Cystic Fibrosis | Phase 2 | 2009-09-01 |
| Completed | Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation Cystic Fibrosis | Phase 3 | 2009-08-01 |
| Completed | Drug-Drug Interaction Study of VCH-222 and Telaprevir in Healthy Subjects Hepatitis C | Phase 1 | 2009-08-01 |
| Completed | Virology Follow up Study in Subjects Previously Treated With Telaprevir Hepatitis C | — | 2009-06-01 |
| Completed | Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation Cystic Fibrosis | Phase 3 | 2009-06-01 |
| Withdrawn | A Phase I Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors Refractory Solid Tumors | N/A | 2009-04-01 |
| Completed | Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection Hepatitis C | Phase 1 / Phase 2 | 2009-04-01 |
| Completed | Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene Mutation Cystic Fibrosis | Phase 2 | 2009-03-01 |
| Completed | Single and Multiple Dose Escalation Study of VX-509 in Healthy Subjects Healthy | Phase 1 | 2008-10-01 |
| Completed | A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Ch Hepatitis C | Phase 3 | 2008-10-01 |
| Completed | A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genot Hepatitis C | Phase 3 | 2008-03-01 |
| Completed | Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C HCV Infection | Phase 1 | 2007-11-01 |
| Completed | A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-95 Hepatitis C | Phase 2 | 2007-10-01 |
| Completed | Study of Telaprevir in Subjects With Hepatic Impairment Hepatic Insufficiency | Phase 1 | 2007-09-01 |
| Terminated | AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer Pancreatic Cancer | Phase 2 | 2007-06-01 |
| Completed | Safety Study of Ivacaftor in Subjects With Cystic Fibrosis Cystic Fibrosis | Phase 2 | 2007-05-01 |
| Completed | A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3) Hepatitis C | Phase 2 | 2007-02-01 |
| Completed | A Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702 Rheumatoid Arthritis | Phase 2 | 2006-11-01 |
| Completed | A Proof-of-concept Study of VCH-759 for the Treatment of Hepatitis C-infection. Hepatitis C, Chronic | Phase 1 / Phase 2 | 2006-10-01 |
| Completed | Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C Chronic Hepatitis C | Phase 2 | 2006-08-01 |
| Completed | Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C Chronic Hepatitis C | Phase 2 | 2006-06-01 |
| Completed | Trial of AVN-944 in Patients With Advanced Hematologic Malignancies Acute Leukemia, Chronic Leukemia, Multiple Myeloma | Phase 1 | 2006-01-01 |
| Completed | Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C Hepatitis C | Phase 2 | 2005-12-01 |
| Completed | VX-950 and Peginterferon for Hepatitis C Hepatitis C | Phase 1 | 2005-10-01 |
| Completed | Phase 2 Clinical Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702 Rheumatoid Arthritis | Phase 2 | 2005-06-01 |
| Completed | A Safety Study for Cethrin (BA-210) in the Treatment of Acute Thoracic and Cervical Spinal Cord Injuries Spinal Cord Injury | Phase 1 / Phase 2 | 2005-02-01 |
| Completed | Phase 2 Clinical Study in Psoriasis With Oral Investigational Drug VX-765 Psoriasis | Phase 2 | 2004-12-01 |
| Completed | Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C Hepatitis C, Hepatitis | Phase 2 | 2004-07-01 |
| Terminated | VX-710, Doxorubicin, and Vincristine for the Treatment of Patients With Recurrent Small Cell Lung Cancer Lung Cancer | Phase 2 | 1998-12-01 |
| Approved For Marketing | VX-445/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients Heterozygous for F508del Mutation and Cystic Fibrosis | — | — |
| Approved For Marketing | Tezacaftor/Ivacaftor Combination Therapy Expanded Access Program for Patients 12 Years of Age and Older With C Cystic Fibrosis | — | — |
| Approved For Marketing | VX-770 Expanded Access Program Cystic Fibrosis | — | — |
| Approved For Marketing | ELX/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients With at Least One F508del Mutation Cystic Fibrosis | — | — |